AUTHORS
Gautam Borthakur, MD, Helena Agerstam, MD2, Guillermo Montalban-Bravo, MD3, Maro Ohanian, DO4, Yesid Alvarado Valero, MD5, Abhishek Maiti, MBBS6, Naveen Pemmaraju, MD7, Ian Bouligny, M.D.8, Thoas Fioretos, Professor9, Guillermo Garcia-Manero, MD10
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 Lund University, Lund, Sweden, Lund, Sweden
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background: Interleukin-1 receptor accessory protein (IL1RAP) is aberrantly expressed on leukemia stem cells (LSC) in acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS) and participates in interleukin-1 signaling. Nadunolimab is an IL1RAP-targeting antibody designed to induce antibody-dependent cellular cytotoxicity and inhibit interleukin-1 alpha/beta signaling. We report initial safety, efficacy and recommended phase 2 dose (RP2D) from an ongoing phase 1b/2a study of nadunolimab combined with azacitidine, with venetoclax in relapsed/refractory (R/R) AML and without venetoclax in higher-risk MDS (NCT06548230).
Methods: This 2-arm study uses a 3+3 dose-escalation lead-in evaluating 2 dose levels of nadunolimab (1 mg/kg and 2.5 mg/kg) in each arm, with standard dosing of azacitidine and venetoclax. Arm 1 is enrolling patients with Revised International Prognostic Scoring System (IPSS-R) intermediate/high/very-high-risk MDS who are untreated or have received up to 2 prior therapies. Untreated patients are required to have high-risk cytogenetics or mutations and unlikely to achieve a robust response to azacitidine alone. Arm 2 is enrolling patients with European LeukemiaNet (ELN) 2022-defined R/R AML receiving first or second salvage therapy, including patients with hypomethylating agent-treated MDS or chronic myelomonocytic leukemia who progressed to AML. In cycle 1, both arms receive nadunolimab on days 1, 8, and 21 and azacitidine on days 8-14; patients with AML also receive venetoclax on days 8-35. Thus, cycle 1 incorporates a 7-day nadunolimab monotherapy window (days 1-7), enabling assessment of early pharmacodynamic and cellular effects attributable to nadunolimab alone. From cycle 2, 28-day cycles comprise nadunolimab on days 1 and 14 and azacitidine on days 1-7; patients with AML receive venetoclax on days 1-21. Responses are categorized using International Working Group 2023 criteria for MDS and ELN 2017 criteria for AML. Translational studies include multi-dimensional flow cytometry, single-cell RNA sequencing, cytokine profiling, and broad gene panel analysis.
Results: Twenty-two patients have been enrolled (Data cut-off: June 30th, 2026); 3 patients in each arm received dose level 1 and the remaining patients received dose level 2. Nadunolimab 2.5 mg/kg was selected as RP2D in combination with azacitidine with or without venetoclax. Nineteen patients completed at least 1 cycle and are evaluable (MDS, n=10; AML, n=9). Median age was 72 years (range, 38-86), and 14 patients (74%) were male.
Among patients with MDS (untreated, n =9), IPSS-R risk was intermediate in 5, high in 4, and very high in 1; 4 had TP53 mutations and 5 had ASXL1 and/or RUNX1/GATA2 mutations. Seven of 10 patients (70%) achieved a response (CR, n=2; CRh, n=2; and CR with unilineage hematologic improvement [CRuni], n=3). Two additional subjects, without progression, are continuing therapy after C1 and 1 discontinued because of progressive disease.
All patients with AML (median number of prior therapies=2) had adverse-risk disease; 3 had MECOM rearrangements and 1 had a TP53 mutation. Three of 9 patients with AML (33%) responded: 1 achieved complete remission (CR), 1 CR with partial hematologic recovery (CRh) and 1 achieved a morphologic leukemia-free state (MLFS). One patient with MECOM-rearranged AML who was refractory to 1 cycle of FLAG-IDA achieved CRh and proceeded to stem cell transplantation. A patient with secondary AML previously treated with lenalidomide remains in CR, whereas a patient with STAG2- and RUNX1-mutated AML after 2 prior lines achieved MLFS and progressed after cycle 3.
Reported grade 3/4 events were neutropenia (n=11), thrombocytopenia (n=5), infections (n=5; including 1 enterocolitis and 1 pneumonia), infusion-related reaction (n=1), and subdural bleeding (n=1). The infusion-related reaction was likely related to nadunolimab; all other listed grade 3/4 events were considered unlikely related to nadunolimab. Enrollment and translational studies are ongoing.
Conclusions: Initial results demonstrate acceptable safety profile and promising clinical activity of nadunolimab-based combinations in both higher-risk MDS and adverse-risk R/R AML, including responses in molecularly high-risk disease. Most grade 3/4 adverse events were considered unlikely related to nadunolimab. These findings support continued enrollment in phase 2a expansion and planned biomarker studies.
DISCLOSURES
Gautam Borthakur, MD: Ubix Therapeutics - Research Funding; Polaris Pharmaceuticals - Research Funding; Epigenetix - Research Funding; Astex Pharmaceuticals - Research Funding; Aptevo Therapeutics - Research Funding; Lava Therapeutics - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony)